Qianben Wang Laboratory: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
<center><font face="lucida fax" style= "color:Yellow" size="+2">'''Laboratory of Cancer Epigenomics'''</font></center> | <center><font face="lucida fax" style= "color:Yellow" size="+2">'''Laboratory of Cancer Epigenomics'''</font></center> | ||
<br> | <br> | ||
<center><font face="lucida fax" style= "color:Yellow" size="+1">'''Department of | <center><font face="lucida fax" style= "color:Yellow" size="+1">'''Department of Cancer Biology and Genetics, The Ohio State University'''</font> | ||
<br> | <br> | ||
[[Wang | <font face="lucida fax" style="color:#ffffff" size="+1"> '''Home''' </font>]] | [[Wang | <font face="lucida fax" style="color:#ffffff" size="+1"> '''Home''' </font>]] | ||
Revision as of 16:01, 1 July 2016
|
The schematic diagram of androgen receptor binding element (ARBE)-directed AR transcriptional regulation. Upper panel shows that agonist-bound AR (red) recognizes an agonist-ARBE in an agonist-specific manner, whereas the bottom panel indicates that antagonist-bound AR (blue) binds to an antagonist-ARBE in an antagonist-dependent manner. The binding of AR to two distinctly different motifs leads to distinct transcriptional outcomes in prostate cancer. The crystal structures of the DNA binding domain (DBD), dihydrotestosterone-ligand binding domain (DHT-LBD) and bicalutamide-LBD are modified from 1R4I, 1T7T and 1Z95, respectively.
|
